Disclosed are methods of treating an individual, for example, a human individual, or more particularly a pediatric individual, having a disease characterized by liver fibrosis, comprising administering a therapeutically effective amount of one or both of a Complement Factor B inhibitor and a Complement Factor P (“CFP” or “properdin”) inhibitor, e.g., anti-CFP antibody and/or anti-CFB antibody or the respective antigen-binding fragment(s) thereof. Exemplary disease states include, but are not limited to, biliary atresia and post-Kasai biliary atresia.

Disclosed are methods of treating an individual, for example, a human individual, or more particularly a pediatric individual, having a disease characterized by liver fibrosis, comprising administering a therapeutically effective amount of one or both of a Complement Factor B inhibitor and a Complement Factor P (“CFP” or “properdin”) inhibitor, e.g., anti-CFP antibody and/or anti-CFB antibody or the respective antigen-binding fragment(s) thereof. Exemplary disease states include, but are not limited to, biliary atresia and post-Kasai biliary atresia.

A synergistic bactericide and bacteriostatic organic sanitizing/disinfectant/cleaning formulation of acetic acid and propionic acid or salts thereof, having a ratio acetate (A): propionate (P) from 4:100 to 20:1, dissolved in water and diluted as required, to a final concentration in the range of 0.5% w/v to 50% w/v of the mixture in the formulation. Particularly, the present formulation comprising 0.03-15% w/v of acetate buffer and 0.04-17.50% w/v and a q.s.p filtered drinking water, pH 5-6 to be used to the food industry as a Generally Recognized as Safe Compound (GRAS), and having a significantly increased sanitizing and sterilization effect on food as well inert hard, semi-hard and soft surfaces, being safe, environmentally friendly, of broad-spectrum and high efficiency. Such foods can be selected from harvested or fresh fruits and vegetables. Such hard surfaces can be selected from domestic surfaces including floors and furniture, industrial surfaces; and hospital surfaces including medical or dental tools and equipment surfaces. It is useful to combating and/or eliminating microorganisms selected from Listeria monocytogenes, Salmonella enterica, Escherichia coli, Staphylococcus aureus, Botrytis cinerea, Pseudomonas aeruginosa, Pseudomonas syringae, Klebsiella pneumoniae, Bacillus cereus, Bacillus subtilis as well other pathogenic microorganisms or its biofilms. It can be also used as antimicrobial additive.

A synergistic bactericide and bacteriostatic organic sanitizing/disinfectant/cleaning formulation of acetic acid and propionic acid or salts thereof, having a ratio acetate (A): propionate (P) from 4:100 to 20:1, dissolved in water and diluted as required, to a final concentration in the range of 0.5% w/v to 50% w/v of the mixture in the formulation. Particularly, the present formulation comprising 0.03-15% w/v of acetate buffer and 0.04-17.50% w/v and a q.s.p filtered drinking water, pH 5-6 to be used to the food industry as a Generally Recognized as Safe Compound (GRAS), and having a significantly increased sanitizing and sterilization effect on food as well inert hard, semi-hard and soft surfaces, being safe, environmentally friendly, of broad-spectrum and high efficiency. Such foods can be selected from harvested or fresh fruits and vegetables. Such hard surfaces can be selected from domestic surfaces including floors and furniture, industrial surfaces; and hospital surfaces including medical or dental tools and equipment surfaces. It is useful to combating and/or eliminating microorganisms selected from Listeria monocytogenes, Salmonella enterica, Escherichia coli, Staphylococcus aureus, Botrytis cinerea, Pseudomonas aeruginosa, Pseudomonas syringae, Klebsiella pneumoniae, Bacillus cereus, Bacillus subtilis as well other pathogenic microorganisms or its biofilms. It can be also used as antimicrobial additive.

Disclosed are acidic feminine intimate cleansing compositions having a pH in the range of from 3 to 5, which further necessarily comprises at least: as a primary antimicrobial active constituent, lactic acid, which may optionally be a substituted lactic acid and/or derivative thereof; and which composition further includes an anionic constituent system which boosts the antimicrobial efficacy of the primary lactic acid constituent present; and which compositions feature low irritation, and good antimicrobial efficacy against certain species of bacteria. Treatment processes using the feminine intimate cleansing composition in treatment of the groin area of human females, and vendible products containing the feminine intimate cleansing compositions are also disclosed.

Disclosed are acidic feminine intimate cleansing compositions having a pH in the range of from 3 to 5, which further necessarily comprises at least: as a primary antimicrobial active constituent, lactic acid, which may optionally be a substituted lactic acid and/or derivative thereof; and which composition further includes an anionic constituent system which boosts the antimicrobial efficacy of the primary lactic acid constituent present; and which compositions feature low irritation, and good antimicrobial efficacy against certain species of bacteria. Treatment processes using the feminine intimate cleansing composition in treatment of the groin area of human females, and vendible products containing the feminine intimate cleansing compositions are also disclosed.

Disclosed are acidic feminine intimate cleansing compositions having a pH in the range of from 3 to 5, which further necessarily comprises at least: as a primary antimicrobial active constituent, lactic acid, which may optionally be a substituted lactic acid and/or derivative thereof; and which composition further includes an anionic constituent system which boosts the antimicrobial efficacy of the primary lactic acid constituent present; and which compositions feature low irritation, and good antimicrobial efficacy against certain species of bacteria. Treatment processes using the feminine intimate cleansing composition in treatment of the groin area of human females, and vendible products containing the feminine intimate cleansing compositions are also disclosed.

In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.